Lenders raise concerns over bid to restore failed pipeline sale

Industry stakeholders said the case has moved beyond a typical transaction dispute into something that tests how the industry handles valuation, process integrity, and national interest when strategic assets are involved.

For lenders and other stakeholders, the case has become a test of governance and institutional discipline, particularly given the strategic importance of the asset involved.

The Amukpe-Escravos Pipeline has, in recent years, evolved into a critical evacuation route as constraints on alternative corridors have persisted. With throughput capacity of 160,000 barrels per day and uptime consistently above 95 per cent, it is regarded as a high-value infrastructure asset whose pricing is expected to reflect both performance and strategic relevance.

It is that valuation which now sits at the centre of the dispute.

Transaction documents indicated that the original $243 million offer had already met resistance from a syndicate of lenders who questioned the assumptions underpinning the figure. Their concern was that the valuation did not align with the asset’s operational reality or prevailing market conditions.

An independent assessment conducted in 2025 placed the same stake significantly higher, with estimates approaching $600 million under reasonable assumptions.

Analysts said the difference was substantial and, in the context of a strategic national asset, raised clear concerns about value preservation.

For lenders, the implication is direct. Proceeding based on the earlier benchmark risks locking in a transaction at a level materially below current market value.

The complications extend beyond pricing. Industry analysts noted that the earlier transaction process unfolded during a period of limited alignment among key financial stakeholders. Subsequent restructuring of the financing framework, supported by improved coordination between lenders and relevant institutions, has since introduced clearer parameters for how any divestment should be undertaken.

Following the exit of the original bidder, Conpurex Limited emerged without a clearly defined transition process, and allegedly failed to meet its financial commitments while seeking to reopen settled terms. Among the proposed revisions were provisions to transfer regulatory approval risks back to the seller and to introduce interest claims on refundable sums. Lenders described these as commercially untenable and indicative of a process that had become inconsistent.

According to analysts, the lending syndicate was not simply concerned that the deal failed, but that a process widely regarded as compromised was being given renewed effect through administrative carryover.

They noted that if a terminated transaction could be revived without a formal restart, the distinction between concluded and ongoing processes begins to erode, which, in turn, weakens contractual certainty and introduces caution into capital allocation decisions.

For institutions already exposed to the asset, the risk is immediate.

Lenders are understood to be pressing for a reset. Their position is that the September 2025 approval should be revisited rather than implemented. A process that has lost both commercial coherence and procedural integrity, they argued, cannot form the basis of a binding outcome.

They argued that the way forward was to reverse the approval, appoint an independent adviser, and return the asset to the market through a transparent and competitive process that reflects current value.

They warned that anything less than a reevaluation of the transaction risks setting a precedent that extends beyond a single transaction as this would suggest that a process can be adjusted after the fact, that valuation benchmarks can lag reality without consequence, and that discipline in the transfer of strategic assets is open to interpretation.

Analysts cautioned that for an industry built on long-term capital and measured risk, that conclusion is not a trivial signal, but a defining one.